HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].

Abstract
Seven patients with gynecologic infections were treated with the new carbapenem class of antibiotic, imipenem/cilastatin sodium (MK-0787/MK-0791) at a dose level of 500 mg/500 mg or 250 mg/250 mg administered intravenously every 12 hours for 5 days. The results obtained were as follows. Clinical effects of MK-0787/MK-0791 were analyzed in 7 patients, including 1 case with pelvic peritonitis, 2 cases with endometritis, adnexitis and pelvic peritonitis, abdominal abscess, vaginal cuff infection and parametritis, and pyometra. Excellent clinical response was seen in 3 cases and good response in 4 cases. No side effect nor abnormal finding in clinical laboratory values was seen in all patients.
AuthorsK Okamura, M Nakakuki, K Yamada, N Ikeno, M Watanabe, K Takahashi, K Muraguchi, A Saito, T Wakisaka, H Murai
JournalThe Japanese journal of antibiotics (Jpn J Antibiot) Vol. 39 Issue 6 Pg. 1526-30 (Jun 1986) ISSN: 0368-2781 [Print] Japan
PMID3463794 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Cyclopropanes
  • Drug Combinations
  • Thienamycins
  • Cilastatin
  • Imipenem
  • Dipeptidases
Topics
  • Adult
  • Bacterial Infections (drug therapy)
  • Cilastatin
  • Cyclopropanes (administration & dosage, therapeutic use)
  • Dipeptidases (antagonists & inhibitors)
  • Drug Combinations
  • Drug Evaluation
  • Female
  • Genital Diseases, Female (drug therapy)
  • Humans
  • Imipenem
  • Infusions, Intravenous
  • Middle Aged
  • Thienamycins (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: